Skip to main content

Table 1 Comparisons of baseline demographic, clinical and clinicopathologic characteristics between the derivation and validation groups

From: Prediction of three lipid derivatives for postoperative gastric cancer mortality: the Fujian prospective investigation of cancer (FIESTA) study

Characteristics Derivation group Validation group P
Number 1506 1506  
Age (years) 58.47 (11.09) 58.76 (11.30) 0.503
Males 72.78% (1096) 75.9% (1143) 0.051
Ever smokers 18.39% (277) 18.53% (279) 0.925
Ever drinkers 5.84% (88) 5.31% (80) 0.525
Family cancer history (+) 8.43% (127) 8.7% (131) 0.795
Body mass index (kg/m2) 22.72 (3.14) 22.91 (3.01) 0.104
Systolic blood pressure (mmHg) 124.16 (19.03) 124.84 (19.92) 0.353
Diastolic blood pressure (mmHg) 76.85 (11.37) 77.43 (11.51) 0.179
Fasting blood glucose (mmol/L) 6.21 (2.48) 6.19 (2.43) 0.853
AI 3.95 (2.28) 3.88 (1.93) 0.209
THR 1.41 (1.47) 1.36 (1.27) 0.339
LHR 3.30 (1.79) 3.28 (1.56) 0.505
TNM stage    0.122
 I 12.44% (177) 11.76% (167)  
 II 15.95% (227) 13.87% (197)  
 III 54.67% (778) 59.01% (838)  
 IV 16.94% (241) 15.35% (218)  
Lauren’s classification    0.551
 Intestinal type 39.77% (552) 38.04% (528)  
 Diffuse type 60.23% (836) 61.96% (860)  
Tumor embolus    0.976
 Positive 39.01% (541) 38.95% (541)  
 Negative 60.99% (846) 61.05% (848)  
Tumor size (cm) 5.55 (2.85); 5 (3.5, 7) 5.66 (3.13); 5 (3.5, 7) 0.337
Number of lymph node metastasis 5.60 (6.91); 3 (0, 8) 5.70 (7.10); 3 (0, 8) 0.724
  1. Data are represented as mean (standard deviation) or median (interquartile range) or percentage (count)
  2. Abbreviations: AI atherogenic index, THR the triglyceride to high-density lipoprotein cholesterol ratio, LHR the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio, TNM tumor-node-metastasis